alecsat
Cell therapyexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00891345)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, passive
Tumor antigens immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- alecsat
- alecsat cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04609215 | Phase 1/Phase 2 (Phase 2) | Apr 21, 2020 | CytoVac A/S, Government of Denmark, University of Southern Denmark |
| NCT02799238 | Phase 2 | Mar 1, 2016 | CytoVac A/S |
| NCT02060955 | Phase 2 | Feb 1, 2014 | CytoVac A/S |
| NCT01984658 | Phase 1 | Oct 1, 2013 | CytoVac A/S, University of Copenhagen |
| NCT01588769 | Phase 1 | Aug 1, 2011 | CytoVac A/S |
| NCT01422850 | Phase 1 | Aug 1, 2011 | CytoVac A/S, Frederikssund Hospital |
| NCT00891345 | Phase 1 | Apr 1, 2009 | CytoVac A/S, Frederikssund Hospital |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CytoVac A/S | For profit | 7 | 6 | 2 | 2009 |
| Frederikssund Hospital | Academic/Hospital | 2 | 0 | 1 | 2009 |
| Government of Denmark | Government | 1 | 0 | 1 | 2020 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Southern Denmark | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1